BioNxt Solutions Inc.
BNXTF
$0.25
$0.000.00%
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -345.45% | -34.40% | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -345.45% | -34.40% | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -345.45% | -34.40% | -- | -- |
| SG&A Expenses | 65.16% | 87.36% | 34.45% | 79.12% | 80.43% |
| Depreciation & Amortization | 119.51% | -80.37% | -76.33% | -70.66% | -123.84% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 56.65% | 61.62% | -5.32% | 49.05% | 27.96% |
| Operating Income | -56.65% | -63.37% | 4.93% | -49.28% | -28.36% |
| Income Before Tax | -121.91% | -69.69% | -8.34% | -31.98% | -17.86% |
| Income Tax Expenses | -- | -120.90% | -- | -- | -- |
| Earnings from Continuing Operations | -121.91% | -66.16% | -8.34% | -31.98% | -17.86% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -121.91% | -66.16% | -8.34% | -31.98% | -17.86% |
| EBIT | -56.65% | -63.37% | 4.93% | -49.28% | -28.36% |
| EBITDA | -58.58% | -66.50% | 3.67% | -53.22% | -28.98% |
| EPS Basic | -105.04% | -53.66% | -4.21% | -24.62% | -11.21% |
| Normalized Basic EPS | -65.22% | -51.79% | -1.69% | -21.95% | -2.99% |
| EPS Diluted | -105.04% | -53.66% | -4.21% | -24.62% | -11.21% |
| Normalized Diluted EPS | -65.22% | -51.79% | -1.69% | -21.95% | -2.99% |
| Average Basic Shares Outstanding | 8.56% | 7.48% | 4.09% | 5.77% | 5.86% |
| Average Diluted Shares Outstanding | 8.56% | 7.48% | 4.09% | 5.77% | 5.86% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |